Physician profile
Daniel Dries
NPI 1255367306
$2,347.19
in general payments reported to CMS, 2019-2025
21 companies · $20.33 in 2025
The $20.33 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.80 · 2021: $479 · 2022: $332 · 2023: $845 · 2024: $640 · 2025: $20.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,473 · Education: $32.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,472.90 |
| Education | $32.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.52 | 2021-2024 | Jardiance |
| Abbott Laboratories | $272.57 | 2021-2024 | Cardiomems, Aveir |
| Novartis Pharmaceuticals Corporation | $258.73 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $223.09 | 2021-2024 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $221.85 | 2022-2024 | Verquvo, Winrevair |
| Impulse Dynamics (USA) INC. | $187.40 | 2024 | Optimizer |
| Pfizer INC. | $153.71 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $114.93 | 2022-2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $96.42 | 2021-2023 | Farxiga |
| Alnylam Pharmaceuticals INC. | $87.24 | 2024 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $77.38 | 2021-2024 | Lifevest |
| Daiichi Sankyo INC. | $58.98 | 2022-2023 | Injectafer |
| Kestra Medical Technology Services, INC. | $57.59 | 2023-2024 | Assure Wcd |
| Boston Scientific Corporation | $35.95 | 2023 | Resonate El Icd Vr |
| United Therapeutics Corporation | $34.57 | 2024 | Tyvaso |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $33.50 | 2023-2024 | |
| Abiomed | $32.24 | 2021 | |
| Cvrx, INC. | $22.64 | 2023 | Barostim Neo System |
| Scpharmaceuticals INC. | $18.23 | 2023 | |
| Janssen Pharmaceuticals, INC | $12.65 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.